Related Experiment Video
Updated: May 9, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma
Oula K Dagher1,2, Martin Pedard3,4,5, Darel Martinez Bedoya3,4,5
1Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Abstract:
Traditional viral-based chimeric antigen receptor (CAR) T cell therapies have vanquished multiple blood malignancies with decade-long remissions yet struggle against solid tumors. Nonviral engineering of CAR T cells via electroporation or lipid nanoparticle (LNP) delivery of CAR-encoding mRNA results in highly efficient yet transient CAR expression, challenging the adequacy of available preclinical models for mRNA-based CAR T cell evaluation. This study presents a unique three-pronged approach that combines mRNA-based CAR T cells, multi-targeting of glioblastoma (GBM)-associated receptors, and maximal surgical resection as a novel and readily translatable platform for preclinical evaluation of mRNA-based CAR T cells against solid tumors. We performed head-to-head in vitro and in vivo analyses of mRNA-based CAR T cells generated using different expansion conditions, mRNA delivery methods, or combination approaches. Besides potent in vitro cytotoxicity, our findings unveil a therapeutic window of anti-tumor efficacy, as well as robust and durable complete remissions in xenograft mouse models of GBM receiving maximal surgical resection and locoregional injections of multivalent CAR T cells (MVCAR). Such efficacies were significantly better in 5-day expanded versus quiescent T cells. Interestingly, MVCAR T cells were superior to pooled CAR T cells (CARPool) expressing the same CAR scFv combinations in an orthotopic resection model of GBM.
Insights
This study introduces a novel mRNA-based chimeric antigen receptor (CAR) T cell therapy platform for glioblastoma (GBM). The approach combines multi-targeting CAR T cells with surgery, achieving durable remissions in preclinical models.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Viral-based chimeric antigen receptor (CAR) T cell therapies are effective against blood cancers but limited against solid tumors.
- Nonviral mRNA delivery for CAR T cells offers transient expression, posing challenges for preclinical evaluation.
- Glioblastoma (GBM) remains a difficult-to-treat solid tumor with poor prognosis.
Purpose of the Study:
- To develop and evaluate a novel platform for preclinical assessment of mRNA-based CAR T cells against solid tumors, specifically GBM.
- To investigate the efficacy of multi-valent CAR T cells (MVCAR) combined with maximal surgical resection.
- To compare different CAR T cell expansion conditions and delivery methods for mRNA-based therapies.
Main Methods:
- Generated mRNA-based CAR T cells using various expansion conditions and delivery methods.
- Conducted head-to-head in vitro and in vivo analyses in xenograft mouse models of GBM.
- Evaluated the combination of MVCAR T cells with maximal surgical resection and locoregional injections.
Main Results:
- mRNA-based CAR T cells demonstrated potent in vitro cytotoxicity against GBM.
- The combined approach of MVCAR T cells, maximal surgical resection, and locoregional injection achieved durable complete remissions in vivo.
- Five-day expanded T cells showed significantly better efficacy compared to quiescent T cells.
- MVCAR T cells outperformed pooled CAR T cells (CARPool) in an orthotopic GBM resection model.
Conclusions:
- A novel, translatable platform combining mRNA-based MVCAR T cells, multi-targeting, and maximal surgical resection shows promise for preclinical evaluation against GBM.
- This platform enables robust assessment of mRNA-based CAR T cell therapies for solid tumors.
- Optimized T cell expansion and multivalent targeting are critical for enhancing therapeutic efficacy in GBM treatment.
More Related Videos
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
